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This study aimed to search the correlation among immunological profiles and clinical phenotypes of scleroderma in well-
characterized groups of scleroderma patients, comparing forty-nine scleroderma patients stratified according to specific clinical
phenotypes with forty-nine healthy controls. Five immunological cell subpopulations (B, CD4+ and CD8+ T-cells, NK, and
monocytes) and their respective stages of apoptosis and activation were analyzed by flow cytometry, in samples of peripheral blood
mononuclear cells (PBMCs). Analyses of results were stratified according to disease stage, time since the diagnosis, and visceral
damage (pulmonary fibrosis, pulmonary hypertension, and cardiac affliction) and by time of treatment with corticosteroids. An
increase in the percentages of monocytes and a decrease in the B cells were mainly related to the disease progression. A general
apoptosis decrease was found in all phenotypes studied, except in localized scleroderma. An increase of B and NK cells activation
was found in patients diagnosed more than 10 years ago. Specific cell populations like monocytes, NK, and B cells were associated
with the type of affected organ.This study shows how, in a heterogeneous disease, proper patient’s stratification according to clinical
phenotypes allows finding specific cellular profiles. Our data may lead to improvements in the knowledge of prognosis factors and
to aid in the analysis of future specific therapies.
1. Introduction
Scleroderma is a rare autoimmune disease of unknown
etiology which affects thousands of people around the world.
Its prevalence is estimated to be between 15 and 35 cases
per 100000 inhabitants [1–3]. Its first symptoms can be seen
around the third and fourth decade of the life but, in some
cases, symptoms can exist for several years without a correct
diagnosis. Scleroderma is three times more common in
women than men. The disease is not linked in any consistent
way to race, season, geography, occupation, or socioeconomic
status. Environmental etiologies are nonetheless possible [1].
Scleroderma is a complex autoimmune disease character-
ized by fibrosis in all the organs, although its name is derived
from the fibrosis of skin caused by the disease. Damage in the
endothelium seems to be the initial lesion responsible for the
cascade of events that results in the disease [4, 5] leading three
main types of alterations: vascular occlusion, immune system
alterations, and connective tissue proliferation.
Fibrosis of the internal organs leads to respiratory prob-
lems, dysphagia, bowel alterations, and kidney and cardiac
dysfunctions; these complications lead to marked disability,
loss of quality of life, and high rates of mortality [1]. There
are two main types of scleroderma, localized and systemic.
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Localized scleroderma affects mainly the skin, while systemic
scleroderma may affect many parts of the body. Localized
scleroderma (LSc) can be classified as morphea, linear, or
linear “en coup de sabre.” Systemic scleroderma (SSc) can
be divided into three major subtypes, limited cutaneous sys-
temic sclerosis (lcSSc), diffuse cutaneous systemic sclerosis
(dcSSc) (sclerosis of proximal extremities, trunk, and face),
and systemic sclerosis sine scleroderma (organ fibrosis only;
no skin thickening).
Differences have been described in immunological cell
subpopulations in patients with different types of com-
plications and visceral involvement [6–8]. The results of
studies in scleroderma patients which have investigated
the number and the percentages of lymphocytes [9–12],
their activation [13, 14], and apoptosis states [14, 15] have
shown some discrepancies. Reasons for these discrepancies
are not clearly apparent but could be related to differences
in subtype, stage, and activity of the disease, demographic
characteristics of the patients, and methodological issues
in obtaining and analyzing patient samples [15]. To clarify
these discrepancies, we have studied the relationship between
clinical scleroderma phenotypes and the different cellular
subpopulations in well-characterized groups of scleroderma
patients, comparing their results with healthy controls and
stratifying them according to scleroderma subtypes, time
since the diagnosis of the disease, and presence of compli-
cations (pulmonary fibrosis, pulmonary hypertension, and
cardiac affliction) and by timewith corticosteroids treatment.
Clinical characteristics like gastroesophageal reflux, digital
ulcers, joint involvement, scleroderma renal crisis, or Rodnan
total skin [16] score were not considered phenotypic strata in
this study.
2. Materials and Methods
2.1. Subjects. Scleroderma patients and controls were ascer-
tained from Spanish Association of Scleroderma (AEE), with
the collaboration of the Institute of Rare Diseases Research
(IIER), Instituto de Salud Carlos III (ISCIII), and the Spanish
Federation of Rare Diseases (FEDER). As all scleroderma
patients were prevalent cases, we validated their diagnosis
checking that they met the classification criteria for SSc
established by the ARA in 1980 [17] instead of the new one
established in 2013 by the ACR/EULAR [18].
The identification of the different types of scleroderma
as well as the organ damages was based on clinical features
extracted from the clinical records which were made by
rheumatologists and/or internal medicines specialists at hos-
pitals of Spain. Time elapsed since the onset of the first symp-
toms to the diagnosis of the disease was estimated through
telephone surveys, with the cases who accepted to participate
in this study. Clinicalmedical recordswere revised to confirm
some dates, when necessary criteria for pulmonary fibrosis,
heart lesions, and pulmonary hypertension were obtained
from echocardiography and/or pulmonary function tests
stated in clinical records.
Controls were selected according to the age and gender
of each patient recruited who was responsible for providing
Table 1: Participant distribution by subsets.
Comparison Group Patients
Controls CONT 49
Patients PAT 49
Type of scleroderma
LSc 6
dcSSc 32
lcSSc 11
Time since the diagnosis
of the disease (years)
0–3 13
4–10 15
>11 21
Treatment with
corticoids (years)
No 21
0–3 17
>3 11
Pulmonary fibrosis No 26
Yes 23
Cardiac affliction No 42
Yes 7
Pulmonary hypertension No 31
Yes 18
his/her own controls among his/her friends and/or neighbor-
hoods. Controls demonstrated no clinical findings suggestive
of infections, allergic manifestations, or immunological dis-
orders.
Forty-nine scleroderma patients (43 females and 6males)
and 49 healthy subjects (26 females and 23 males) were
included in the study.Although therewas a higher presence of
females in scleroderma patients than in control group (87.7%
versus 53.06%), the analysis according to sex did not show any
statistically significant association with cellular population
studied. The mean age ± standard deviation in the total
group of patients was 48.0 ± 10.9 years and 48.4 ± 13.1 years
for controls (Table 1). During the assays, thirteen patients
were receiving corticosteroid treatment (11 with prednisone,
1 withmethylprednisolone, and 1 with deflazacort), 4 patients
were undergoing treatment with other immunosuppressive
drugs, and 11 patients were treated with a combination of
an immunosuppressive with a corticosteroid. None of the
patients took the medication in the 12 hours before the
samples were collected. All participants signed an informed
consent inwhich they agreed to participate in the project.The
project was also approved by the Ethics Committee of both
participating institutions (Instituto de Salud Carlos III and
IIS-Fundacio´n Jime´nez Dı´az).
2.2. Isolation of Peripheral BloodMononuclear Cells (PBMCs).
PBMCs from donors were isolated from venous blood by
density gradient sedimentation on Lymphoprep (Comercial
Rafer, Zaragoza, Spain) following the manufacturer’s instruc-
tions and resuspended in freezing medium containing 90%
FBS (Lonza, Verviers, Belgium) and 10% DMSO (Sigma-
Aldrich, St. Louis, USA). The cells were aliquoted into
cryogenic vials and stored in liquid nitrogen until use.
PBMCs were thawed in RPMI 1640 supplemented with
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Figure 1: Characterization of cellular subpopulations analyzed by flow cytometry. FL1: Annexin-V+ cells; FL2: CD3+ or/and CD56+ cells;
FL3: CD4+ cells; FL4: CD19+ or CD8+ cells; FL5: CD25+ cells; SSC: side-scatter detector.
5% FBS inactivated, 1% L-glutamine, 1% peni-streptomycin,
and 1mM sodium pyruvate (Flow Laboratories, Irvine, UK)
and after two washed, the PBMCs were resuspended in
saline buffer and stained according recommendations of the
specific commercial antibody. Quantification and viability
were determined by trypan blue exclusion. Before doing
apoptosis and activation analysis, controlswith freeze PBMCs
samples were carried out for testing quality of assays. Samples
included for analysis had a viability of at least 90%. All
biological samples were collected from the Institute of Rare
Diseases Research Biobank, belonging to European Rare
Diseases Biobank-EuroBioBank.
2.3. Immunophenotyping. Cellular phenotype was analyzed
by flow cytometry using a single PBMCs sample labeled
with a five-color combination of monoclonal antibodies for
Annexin-V-FITC (FL-1) (Ref: ANXVKF-100T, Inmunostep,
Salamanca, Spain), CD3-PE (Ref: CYT-3PE5) and CD56-PE
conjugated (FL-2) (Ref: CYT-56PE) (Vitro-Cytognos, Sala-
manca, Spain), CD4-ECD (FL-3) (Ref: 6604727, Beckman
Coulter, Izasa, Barcelona, Spain), CD8-PC5 (Ref: CYT-8C2)
and CD19-PC5 conjugated (FL-4) (Ref: CYT-19C2) (Vitro-
Cytognos, Salamanca, Spain), and CD25-PC7 (FL-5) conju-
gated (Ref: PN A52882, Beckman Coulter, Izasa, Barcelona,
Spain) by using Cytomics FC500 and CXP software (Beck-
man Coulter, Brea, USA). Unlike other studies, the differ-
ent signal intensities of this combination of fluorochromes
allowed us to analyze several clusters of differentiation at the
same time using only one determination (Figure 1). At least
5,000 events were acquired in a listmode and all the data were
analyzed by cell quest software (CXP Beckman Coulter).
Five-color flow cytometry analysis was performed as
follows. Briefly, 2⋅105 PBMCswere labeled with 20 𝜇L of each
monoclonal antibody (CD3-PE, CD56-PE, CD4-ECD, CD8-
PC5, CD19-PC5, and CD25-PC7 conjugated) and placed in
an ice-water bath for 20 minutes.
After washing with PBS, 20𝜇L of Annexin-V-FITC was
delivered and the tubes were placed in an ice-water bath for
15 minutes in darkness. Then, the cells were resuspended in
200𝜇L of binding buffer (PBS) for immediate flow cytometry
analysis.
Live PBMCs were electronically gated by forward-
and right-angle scatters; different types of cells were then
gated and the percentage and intensity of expression were
evaluated. When the gated cells were uncertain or very
few, the data were excluded. Negative controls included
a human isotype-matched nonrelevant immunoglobulin:
Mouse IgG2a-PE (CYT-IC006PE, Cytognos) and IgG2b-
PE (CYT-IC007PE, Cytognos), IgG1-PECy5 Mouse Isotypic
Control (CYT-IC005C, Cytognos), Mouse IgG2a- PC7 (PN
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Figure 2: Box-plot of B lymphocytes. ∗Statistically significant rela-
tive to controls. ‡Statistically significant relative to patients without
pulmonary hypertension.
A12692, Beckman Coulter), and Mouse IgG1-ECD Isotypic
Control (A07797, Beckman Coulter). Figure 1 (upper panel)
summarizes the selection of cell populations studied: per-
centages of T lymphocytes CD3+CD4+ and CD3+CD8+ were
evaluated for the total number of CD3+ cells. Percentages of B
cells (CD3−CD19+), NK cells (CD3−CD56+), and monocytes
were evaluated regarding total number of cells. Monocytes
were gated based on CD3−CD4+ expression and high side-
scatter (SSC).
After the determination of cellular subpopulations,
the percentages of apoptosis (Annexin-V+) and activation
(CD25+ expression) of each subpopulation were evaluated
regarding their respective overall number of cells (lower panel
of Figure 1).
2.4. Statistical Analysis. Global analysis was performed by
Kruskal-Wallis test and comparisons between groups were
performed using a nonparametric two-tailed Mann-Whitney
test for independent variables. A 𝑃 value of <0.05 was used.
Weused theRprogram for the statistical analysis and the box-
plots design.
3. Results
Table 2 shows the medians of the percentages of each type of
cellular subpopulations studied, as well as their activation or
apoptosis stages, grouped by clinical phenotype.
Significant differences were detected in scleroderma
patients when we compare their results with the control
group. We found a decrease in the percentage of B lympho-
cytes and higher values of monocytes. We did not find any
difference in activation states, although for apoptosis values
we observed a decrease in all the subsets of cells compared to
controls.
According to scleroderma phenotypes, we found a pro-
gressive reduction in the percentages of B lymphocytes in
the most severe phenotypes of the disease (Figure 2); this
decrease in the diffuse systemic variant (𝑃 < 0.01) compared
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Figure 3: Box-plot of overall apoptosis regarding scleroderma
type and presence of PH and PF. ∗Statistically significant relative
to controls. †Statistically significant relative to patients without
pulmonary hypertension.
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Figure 4: Box-plot of activated NK cells. ∗Statistically significant
relative to controls.
to controls was statistically significant. A statistically signif-
icant increase in monocytes was shown relative to controls
(3.35%) only in patients affected by systemic sclerodermas
(7.41% in limited form and 7.91% in diffuse form). No
difference in cell activation was found among scleroderma
phenotypes. As for overall apoptosis, we found a decrease in
systemic but not in localized sclerodermas (Figure 3). Apop-
tosis values by cellular population (Table 2) were decreased
in several cellular subsets in systemic sclerodermas. The
reduction was in all the subsets analyzed in the diffuse form
and B cells and in monocytes in the limited form. Localized
sclerodermas showed an apoptotic decrease in monocytes.
In patients with pulmonary fibrosis (PF), we found a
reduction in the percentages of B lymphocytes (Figure 2) and
an increase of activated NK cells (Figure 4). Patients with
and without fibrosis showed increasedmonocyte percentages
(Table 2) and similar apoptotic profiles.We obtained reduced
percentages in all cell subpopulations except in CD4 T-cells
in patients with PF.
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In the group of patients with pulmonary hypertension
(PH), we found the lowest percentages of B cells (Figure 2).
This groupwas the only onewithout an increase ofmonocytes
(Table 2). We also found significant increases of activated B,
NK, and CD8+ cells. The increase of CD8+ cells is altered
like in pulmonary fibrosis. Regarding apoptosis, we found
decreases in all the subpopulations of patients without pul-
monary hypertension when comparing these subpopulations
to controls. In addition, we found statistically significant
differences when comparing absence and presence of PH,
with lower apoptosis found in the absence of pulmonary
hypertension (Table 2).
We found few significant differences in patients affected
by cardiac affliction (CA) probably due to the low number
of patients tested (𝑛 = 7); we only found an increase of
monocytes (Table 2).
Regarding time since the diagnosis of the disease, we
only found an increase of monocytes in patients diagnosed
from 4 to 10 years (Table 2). Patients diagnosed more than
10 years previously showed an increase in the percentages
of activated B and NK cells; these results were very similar
to those obtained in patients diagnosed from 0 to 3 years
(Table 2). We also found the lowest percentages of apoptosis
in the group of patients diagnosed from 4 to 10 years ago
(Table 2), but a progressive recovery is produced with time,
except for B cells and monocytes.
Regarding to the treatment time with corticosteroids,
thetreatment decreases the percentages of B cells and, in
patients treated during more than 3 years, a reduction of
the percentages of monocytes and their activation state are
produced (Table 2). In this group we also obtained the
smallest percentages of apoptosis (Table 2). In addition, the
group of patients diagnosed from zero to three years had
higher percentages of activated NK cells.
4. Discussion
There have been conflicting results concerning changes in the
immune cell subpopulations involved in scleroderma [11, 19–
21] due to the heterogeneity of the disease and differences in
study methods. In order to shed light on this issue, we have
studied a well-defined clinical population, analyzing both
the cell subpopulations and their activation and apoptosis
stages and also correlating the data with different clinical
phenotypes.
We obtained normal values of T lymphocytes, as has been
described by other authors [11, 20–22]. However, we found
a reduction of B-cells in the worse-prognosis situations of
the disease but higher percentages of monocytes in almost
all SSc subsets. These results can be also correlated with the
conditions of visceral involvement that triggers the worst
prognosis (Figure 2 and Table 2).
The monocyte fraction of peripheral blood contains
precursors to potential regulators of fibrosis [23] such as
fibrocytes and macrophages [18, 24, 25]. Several studies
obtained functional abnormalities and increased numbers of
these cells in scleroderma patients [23, 26–29]. Our results
are consistent with many data that indicate the association
between elevated levels of peripheral blood fibrocytes and
monocytes and diverse forms of organ remodeling such as
renal fibrosis, cirrhosis, or different types of pulmonary fibro-
sis [29]. An abnormal remodeling in scleroderma is usually
more common in systemic sclerodermas [30]. However, our
monocytes results must be considered with caution because
monocytes were not detected directly through aCD14marker
and, instead, were selected indirectly, as CD3−CD4+, and
some monocytes cannot express CD4.
The action of B cells in scleroderma could be related to
their functions in the regulation of the immune response
[31] and antibody production and abnormalities in them can
induce or develop autoimmune diseases like scleroderma.
Analyzing the activation states, we obtained a higher
overall activation in patients in whom the time elapsed since
diagnosis was greater or in patients with visceral involvement
(especially in B and NK cells). Some authors determine that
survival rates of scleroderma patients begin their decline in
the period of time of four to ten years since they go to the
hospital [32, 33]. As detected in our study, the development
of serious visceral involvement portends early mortality in
patientswith scleroderma [32, 34, 35] and is concomitantwith
elevated activation states of immune cells [28, 36, 37].The role
played by NK cells in autoimmune diseases is both a disease-
controlling and a disease-promoting role and NK cells may
be implicated in the onset, maintenance, or progression of
these diseases [38], thus suggesting their involvement in the
scleroderma [39].
Activation markers like CD25 play a role in cell contact
interactions between T-cells and other cells, including fibrob-
lasts. However, the analysis of other lymphocytes activation
markers as CD69 or MHC Class II could be interesting,
especially for determining monocyte activation. Inclusion of
cytokine production from these cell populations could also
enhance information about their states of activation.
Apoptosis values may be difficult to evaluate due to the
method for conserving the cells. In this study, as frozen
cells were used, the freezing effect was checked and was
homogenous in all samples. Annexin V staining precedes
the loss of membrane integrity which accompanies the later
stages of cell death resulting from either apoptotic or necrotic
processes, for that was selected as cellular death marker.
We found a decrease in different subsets in the disease,
possibly because of apoptosis resistance in the cells of sclero-
derma patients. Apoptosis resistance is the primary mecha-
nism leading to the development of fibrotic lesions and could
be one of the reasons why some types of sclerodermas have
more visceral fibrosis and worse prognosis, especially in the
case of diffuse forms, where the apoptosis rates are the lowest.
Some authors [40] have described that, during later phases of
systemic sclerosis, inflammatory events become less intense
and the immune response acts as a low-grade amplifier of
fibrogenesis and microangiopathy, presenting a significant
therapeutic challenge. This could explain the differences that
we have found between the patients analyzed according to
time since diagnosis: a diminution in the beginning of the
disease, which could coincide with the endothelial damage;
after four to ten years, the disease could coincide with the
development of fibrosis in the internal organs, where we have
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obtained apoptosis diminutions; and, finally, until about ten
years following diagnosis, the apoptosis tends to increase and
the fibrosis tends to slow down.
In patients diagnosed more than ten years previously,
the reduction in the apoptosis of B cells and monocytes is
parallel to an increase in the overall activation, especially in
the activation of B andNK cells.This coincides with decreases
in the survival rates of the scleroderma patients [32, 33] and
organ affliction tends to appear in the late-onset stages of the
disease [30].The detected alterations in these subpopulations
could have some influence on survival rates and could be
useful in the prognosis of the disease.
The usual treatment of scleroderma—especially of organ
fibrosis—[30] is based on immunosuppressive drugs and cor-
ticosteroids that increase the apoptosis of the inflammatory
cells [41]. In our results, the treatment seems to increase
the apoptosis in the group treated with corticosteroids from
zero to three years but, in patients with more than three
years treated, the situation reverts to diminished percentages.
This could be one of the reasons that make treatment with
corticosteroids inefficient in patients who have had the
disease for many years. In addition to this, two things must
be taken into account: both kinds of drugs can interfere with
the action of B cells, although they usually do not reduce
their numbers and corticosteroids produce an inhibitory
effect in NK cells [42] but these cells have a lower sensitivity
to these kinds of drugs [43]. These data coincide with our
results where more time is needed to reduce their activation.
However, corticosteroids are useful in monocytes, producing
a reduction in the patients with more time with the disease.
5. Conclusions
In conclusion, an overall decrease in apoptosis and in the
numbers of B cells together with an increase of monocytes
and activated B and NK cells is directly correlated with the
severity of the disease. These results suggest that these cells
contribute to the immunological abnormalities observed in
scleroderma and could announce the appearance of compli-
cations or a worsening in the disease.
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